DZ
DefZone.Net

Kien thuc cong nghe & giai tri

Wiki Article

Retatrutide

Nguồn dữ liệu từ Wikipedia, hiển thị bởi DefZone.Net

Xem trên WikipediaBài ngẫu nhiên khác

Retatrutide
Clinical data
Other namesLY-3437943
Identifiers
  • L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-L-leucyl-L-α-aspartyl-L-lysyl-N6-(N-(19-carboxy-1-oxononadecyl)-L-γ-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-alanyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-L-tyrosyl-L-leucyl-L-leucyl-L-α-glutamylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide
CAS Number
UNII
ChEMBL
Chemical and physical data
  • CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
  • InChI=1S/C221H342N46O68/c1-23-124(11)179(208(322)241-144(83-88-176(291)292)192(306)245-150(105-134-69-75-137(276)76-70-134)196(310)244-148(100-121(5)6)194(308)243-147(99-120(3)4)193(307)240-142(82-87-175(289)290)187(301)230-110-169(282)229-113-173(286)264-92-51-61-161(264)206(320)253-158(116-270)203(317)251-157(115-269)189(303)232-111-170(283)233-128(15)212(326)266-94-53-63-163(266)214(328)267-95-54-64-164(267)213(327)265-93-52-62-162(265)207(321)250-156(114-268)183(226)297)258-200(314)152(103-131-55-41-39-42-56-131)242-185(299)127(14)235-216(331)219(18,19)262-205(319)145(80-85-166(225)279)237-184(298)126(13)234-190(304)140(60-48-50-90-227-172(285)119-335-98-97-334-96-91-228-167(280)86-81-146(215(329)330)236-168(281)65-45-37-35-33-31-29-27-25-26-28-30-32-34-36-38-46-66-174(287)288)238-191(305)141(59-47-49-89-222)239-198(312)154(107-177(293)294)247-195(309)149(101-122(7)8)256-218(333)221(22,109-123(9)10)263-211(325)180(125(12)24-2)259-204(318)160(118-272)252-197(311)151(106-135-71-77-138(277)78-72-135)246-199(313)155(108-178(295)296)248-202(316)159(117-271)254-210(324)182(130(17)274)260-201(315)153(104-132-57-43-40-44-58-132)249-209(323)181(129(16)273)257-171(284)112-231-188(302)143(79-84-165(224)278)255-217(332)220(20,21)261-186(300)139(223)102-133-67-73-136(275)74-68-133/h39-44,55-58,67-78,120-130,139-164,179-182,268-277H,23-38,45-54,59-66,79-119,222-223H2,1-22H3,(H2,224,278)(H2,225,279)(H2,226,297)(H,227,285)(H,228,280)(H,229,282)(H,230,301)(H,231,302)(H,232,303)(H,233,283)(H,234,304)(H,235,331)(H,236,281)(H,237,298)(H,238,305)(H,239,312)(H,240,307)(H,241,322)(H,242,299)(H,243,308)(H,244,310)(H,245,306)(H,246,313)(H,247,309)(H,248,316)(H,249,323)(H,250,321)(H,251,317)(H,252,311)(H,253,320)(H,254,324)(H,255,332)(H,256,333)(H,257,284)(H,258,314)(H,259,318)(H,260,315)(H,261,300)(H,262,319)(H,263,325)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,295,296)(H,329,330)/t124-,125-,126-,127-,128-,129+,130+,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,179-,180-,181-,182-,221-/m0/s1
  • Key:MLOLQJNKXBNWFW-JMUPIODPSA-N

Retatrutide (LY-3437943) is an experimental drug[1] for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist on the GLP-1, GIP, and glucagon receptors.[2][3][4]

Adverse effects

[edit]

The safety profile of retatrutide is still under investigation. Reported side effects have been gastrointestinal symptoms, such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort. An increase in side effects occurred with increased dosages. Less commonly reported side effects have included fatigue, headaches, and mild increases to heart rate. All drugs targeting GLP-1 receptors currently have the potential risk for pancreatitis, gallbladder disease, and gastrointestinal intolerance. These effects have not been linked to retatrutide in current trials. However, long-term outcomes of side effects are still being established.[5]

Mechanism of action

[edit]

GLP-1 receptors improve insulin sensitivity and increase satiety. Retatrutide has shown to increase insulin secretion. Furthermore, agonism of the glucagon receptor increases energy expenditure and promotes fat loss and metabolic activity. With current research, activation of these receptors has overall reduced caloric intake and increased energy expenditure, successfully leading to higher weight loss compared to alternative treatments.[2]

Chemistry

[edit]

Retatrutide is a peptide with the following amino acid sequence[6]

YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³

where letters with superscripted numbers refer to the following chemical modifications:

  • A¹ – 2-aminoisobutyric acid (Aib).
  • L² – leucine modified with an α-methyl substituent (MeL, 2-methylleucine).
  • S³ – L-serinamide (L-serine with the carboxylic acid group replaced with a carboxamide).
  • K⁴ – L-lysine with the amino group at position 6 modified with a side chain; specifically, (AEEA)-(γ-Glu)-(C20 diacid) (where AEEA is 2-[2-(2-aminoethoxy)ethoxy]acetic acid, commonly used as a spacer group in synthetic peptides).

Retatrutide is synthetically engineered and produced using solid-phase peptide synthesis (SPPS). This is when amino acids are added to a peptide chain and attached to solid resin forming a backbone. After the backbone is synthesized, the molecule is cleaved chemically, then purified. Lipidation modifications also occur, meaning a fatty-acid side chain is added to promote reversible binding to albumin. This modification allows for a longer drug half-life, raising compliance as it enables once-weekly dosing.[2]

History

[edit]

Clinical trials

[edit]

Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight).[7][8][5] Retatrutide is also being evaluated in phase 3 clinical trials.[9] Two trials in the phase 3 TRIUMPH program reached primary completion in April 2026: TRIUMPH-1, a master protocol in adults with obesity or overweight, and TRIUMPH-3, in participants with severe obesity and established cardiovascular disease.[10][11][12] A substudy in adults with type 2 diabetes reported differences in total body fat mass between study groups at 36 weeks.[13]

Preclinical and biochemical studies describe receptor activity at GLP-1, GIP, and glucagon receptors.[14] Reports on its development state that it was engineered for activity across these targets.[2]

Systematic reviews and meta-analyses of randomized controlled trials report that retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations.[15][16][17][18][19] Adverse events are most commonly gastrointestinal symptoms such as nausea and diarrhea, with relatively low rates of study discontinuation and infrequent serious adverse events reported during trials.[15][16][17] Safety assessments also indicate a low risk of hypoglycemia and no significant elevation in cardiovascular or hepatic adverse events in non-diabetic populations across published studies.[18][19]

Society and culture

[edit]

Multiple black market sellers of the peptide emerged before approval of the Lilly drug, leading to multiple lawsuits with Lilly as the plaintiff.[1]

Research

[edit]

Retatrutide is under preliminary research for how it may influence obesity-associated cancer progression.[20]

See also

[edit]

References

[edit]
  1. ^ a b Kristin J (12 August 2026). "Lilly files six lawsuits in bid to shut down 'black market' for retatrutide". Biopharma Dive. Retrieved 12 August 2026. In the case of retatrutide, no regulatory agency anywhere in the world has approved the medicine.
  2. ^ a b c d Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. (September 2022). "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept". Cell Metabolism. 34 (9): 1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID 35985340.
  3. ^ Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM (August 2025). "Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare". World Journal of Cardiology. 17 (8) 107991. doi:10.4330/wjc.v17.i8.107991. PMC 12426997. PMID 40949933.
  4. ^ Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Gonzáles-Yovera JG, Ruvalcaba-Barbosa GY, Cura-Rodríguez LD, González-Rodríguez JS, et al. (October 2025). "Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review". World Journal of Gastroenterology. 31 (37) 111435. doi:10.3748/wjg.v31.i37.111435. PMC 12476660. PMID 41025003.
  5. ^ a b Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. (August 2023). "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial". The New England Journal of Medicine. 389 (6): 514–526. doi:10.1056/NEJMoa2301972. PMID 37366315.
  6. ^ "Retatrutide". Compound Report Card. European Bioinformatics Institute, European Molecular Biology Laboratory. n.d. Retrieved August 5, 2024.
  7. ^ "Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight". investor.lilly.com (Press release). Eli Lilly. 26 June 2023. Retrieved 3 July 2023.
  8. ^ Constantino AK (26 June 2023). "Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients". CNBC.com. Retrieved 3 July 2023.
  9. ^ "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) - Lilly Clinical Trials". Lilly Trials. Retrieved 2025-08-24.
  10. ^ "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)". ClinicalTrials.gov. U.S. National Library of Medicine. Retrieved 2026-06-12.
  11. ^ "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)". ClinicalTrials.gov. U.S. National Library of Medicine. Retrieved 2026-06-12.
  12. ^ "Retatrutide Phase 3 Trial for Obesity and CVD Reaches Primary Completion". hipa.ai. Retrieved 2026-06-12.
  13. ^ Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, et al. (August 2025). "Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial". The Lancet. Diabetes & Endocrinology. 13 (8): 674–684. doi:10.1016/S2213-8587(25)00092-0. PMID 40609566.
  14. ^ "Compound: RETATRUTIDE (CHEMBL5095485)". www.ebi.ac.uk. Retrieved 2025-11-24.
  15. ^ a b Tewari J, Qidwai KA, Tewari A, Kaur S, Tewari V, Maheshwari A (2025). "Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis". Expert Review of Clinical Pharmacology. 18 (1–2): 51–66. doi:10.1080/17512433.2025.2450254. PMID 39817343.
  16. ^ a b Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, et al. (2025). "Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials". Proceedings. 38 (3): 291–303. doi:10.1080/08998280.2025.2456441. PMC 12026077. PMID 40291085.
  17. ^ a b Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K (May 2025). "Retatrutide-A Game Changer in Obesity Pharmacotherapy". Biomolecules. 15 (6): 796. doi:10.3390/biom15060796. PMC 12190491. PMID 40563436.
  18. ^ a b Olowo-Oribi BA, Salway RJ (November 2025). "Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes". Academic Emergency Medicine. 32 (11): 1255–1258. doi:10.1111/acem.70088. PMID 40583149.
  19. ^ a b Sinha B, Ghosal S (November 2025). "Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA". Obesity. 33 (11): 2046–2054. doi:10.1002/oby.24360. PMID 40685589.
  20. ^ Marathe SJ, Grey EW, Bohm MS, Joseph SC, Ramesh AV, Cottam MA, et al. (2025-03-14). "Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression". npj Metabolic Health and Disease. 3 (1) 10. doi:10.1038/s44324-025-00054-5. PMC 11908972. PMID 40094000.

Further reading

[edit]